Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit

Cancer(2021)10.1002/cncr.34004Source: DataRank Database

Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit is a research paper published in Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 21 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access21 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:OA: bronzeTopics (17)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Sahira Farooq ORCID,Macartney Welborn ORCID,Rodabe N. Amaria ORCID,Susan Y. Chon ORCID,Adi Diab ORCID

Live enrichment

PubMed:34724197

bronzeLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.34004

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34004

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/cncr.34004

publisherhttps://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34004

MeSH Terms

HumansMelanomaSkin NeoplasmsSkin DiseasesImmunotherapyIncidenceAntibodies, Monoclonal, HumanizedIpilimumabNivolumab

Keywords

MelanomaIpilimumabNivolumabCutaneous Adverse EventsImmune Checkpoint InhibitorsPembrolizumabAnti-cytotoxic T-lymphocyte-associated Antigen 4 (Anti-ctla4)Anti-programmed Death 1 (Anti-pd1)